

REMARKS

The preliminary amendment is made to remove multiple dependencies from claims 8, 16-18, and 31-37, to cancel claims 3-7, 20-23 and 26-30, and to clarify claims 1, 10, 14, 15, 19, 24, 36 and 37. The applicants hereby assert that no new matter has been added.

A new abstract page is supplied to conform to that appearing on the publication page of the WIPO application, but the new Abstract is typed on a separate page as required by U.S. practice.

Claim 1 has been amended to better define the claimed pharmaceutical composition. Claim 1 has been amended to define a pharmaceutical composition comprising: (a) a HMG CoA reductase inhibitor; (b) pyridoxal 5'-phosphate; (c) and a pharmaceutically acceptable carrier. Support for the amendment can be found at page 11, line, 2 and elsewhere in the application.

Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.

If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, Brian R. Dorn (Reg. No. 57,395), at (612)766.6025.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300



Dated: June 23, 2006

By

A handwritten signature in black ink, appearing to be "B. R. Dorn", written over a horizontal line.

Brian R. Dorn
Reg. No. 57,395

BRD/ncb